Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer.
Gemma A, Kudoh S, Ando M, Ohe Y, Nakagawa K, Johkoh T, Yamazaki N, Arakawa H, Inoue Y, Ebina M, Kusumoto M, Kuwano K, Sakai F, Taniguchi H, Fukuda Y, Seki A, Ishii T, Fukuoka M.
Gemma A, et al. Among authors: ando m.
Cancer Sci. 2014 Dec;105(12):1584-90. doi: 10.1111/cas.12550.
Cancer Sci. 2014.
PMID: 25287435
Free PMC article.
Clinical Trial.